logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

NCT#/Phase: NCT03220035
Phase 2
IRB#: 2017-095g
Description: This is a subprotocol of the MATCH trial APEC1621 and is a phase 2 trial of vemurafenib in children with relapsed or refractory solid tumors (including lymphomas, histiocytoses and CNS tumors) harboring specified activating genetic alterations of the BRAF gene. This study aims to determine the objective response rate determined by RECIST.
Inclusion: Individuals who are between 12 months and 21 years of age and given a therapy assignment to MATCH to APEC1621F.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group (COG)
Principal Investigator(s): Carla Golden, MD
Contact(s): Diane Olszewski (510-428-3885 x 3246)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03220035#

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000